$MTNB
Matinas BioPharma Holdings, Inc. Stock $mtnb

$mtnb Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000114420416101865 Filed on May 13, 2016

Income Statement

Concept	2016 Q2	2016 Q1	2015 Q4
Revenue	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$642.6K	$921.7K
YoY Change	-52.57%	-36.36%
% of Gross Profit
Depreciation & Amortization	$13.00K	$12.89K	$10.00K
YoY Change	30.0%	18.75%	-200.0%
% of Gross Profit
Operating Expenses	$1.620M	$2.237M
YoY Change	-34.64%	-14.8%
Operating Profit	-$1.620M	-$2.237M
YoY Change	-32.54%	-12.89%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$3.656K	-$7.122K
YoY Change	33.53%	377.03%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings	-$1.624M	-$2.245M
YoY Change	-32.47%	-12.66%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding	57.59M shares	57.18M shares	57.21M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q2	2016 Q1	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$580.0K	$1.670M	$3.230M
YoY Change	-91.23%	-63.85%	24.71%
Cash & Equivalents	$578.3K	$1.673M	$3.227M
Short-Term Investments
Other Short-Term Assets	$200.0K	$240.0K	$330.0K
YoY Change	-9.09%	26.32%	57.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$770.0K	$1.912M	$3.559M
YoY Change	-88.81%	-60.51%	26.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$380.0K	$364.8K	$377.7K
YoY Change	4.63%	7.61%	11.1%
Goodwill	$1.336M	$1.336M	$1.336M
YoY Change	-3.48%	-3.48%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$50.00K	$120.0K	$120.0K
YoY Change	-77.27%	-45.45%	-45.45%
Total Long-Term Assets	$4.790M	$4.834M	$4.847M
YoY Change	-3.85%	-2.49%	771.27%
TOTAL ASSETS
Total Short-Term Assets	$770.0K	$1.912M	$3.559M
Total Long-Term Assets	$4.790M	$4.834M	$4.847M
Total Assets	$5.560M	$6.746M	$8.406M
YoY Change	-53.13%	-31.15%	150.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$480.0K	$620.6K	$497.8K
YoY Change	-35.62%	32.99%	83.6%
Accrued Expenses	$850.0K	$689.2K	$610.2K
YoY Change	150.12%	-11.73%	-23.99%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$10.00K	$0.00	$10.00K
YoY Change	-66.67%	-100.0%	-75.0%
Total Short-Term Liabilities	$1.340M	$1.320M	$1.129M
YoY Change	17.94%	0.93%	0.92%
LONG-TERM LIABILITIES
Long-Term Debt	$20.00K	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$20.00K	$0.00	$0.00
YoY Change	-97.62%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.340M	$1.320M	$1.129M
Total Long-Term Liabilities	$20.00K	$0.00	$0.00
Total Liabilities	$2.567M	$2.525M	$2.334M
YoY Change	-20.52%	-25.84%	105.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$27.06M	-$25.43M	-$23.19M
YoY Change	42.2%	53.0%	65.01%
Common Stock	$5.760K	$5.760K	$5.719K
YoY Change	1.09%	23.1%	77.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.997M	$4.220M	$6.072M
YoY Change
Total Liabilities & Shareholders Equity	$5.565M	$6.746M	$8.406M
YoY Change	-53.09%	-31.15%	150.07%

Cashflow Statement

Concept	2016 Q2	2016 Q1	2015 Q4
OPERATING ACTIVITIES
Net Income	-$1.624M	-$2.245M
YoY Change	-32.47%	-12.66%
Depreciation, Depletion And Amortization	$13.00K	$12.89K	$10.00K
YoY Change	30.0%	18.75%	-200.0%
Cash From Operating Activities	-$1.100M	-$1.540M	-$1.110M
YoY Change	-50.45%	-33.62%	-53.94%
INVESTING ACTIVITIES
Capital Expenditures	-$30.00K	$0.00	-$30.00K
YoY Change	-25.0%	-100.0%
Acquisitions		$0.00
YoY Change		-100.0%
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$30.00K	$0.00	-$30.00K
YoY Change	-25.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	30.00K	-10.00K	10.00K
YoY Change	-99.29%	-100.23%
NET CHANGE
Cash From Operating Activities	-1.100M	-1.540M	-1.110M
Cash From Investing Activities	-30.00K	0.000	-30.00K
Cash From Financing Activities	30.00K	-10.00K	10.00K
Net Change In Cash	-1.100M	-1.550M	-1.130M
YoY Change	-155.56%	-176.35%	-53.11%
FREE CASH FLOW
Cash From Operating Activities	-$1.100M	-$1.540M	-$1.110M
Capital Expenditures	-$30.00K	$0.00	-$30.00K
Free Cash Flow	-$1.070M	-$1.540M	-$1.080M
YoY Change	-50.92%	-33.76%	-55.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	921711	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	3559120	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	1911580	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	377723	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	364832	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	231797	USD
CY2016Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	138017	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1448413	USD
CY2016Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	11261	USD
CY2015Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	0	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-11261	USD
CY2016Q1	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
CY2015Q1	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	753346	USD
CY2015Q1	mtnb	Percentage Of Approval Shareholders PercentageOfApprovalShareholders	1	pure
CY2016Q1	us-gaap	Goodwill Subsequent Recognition Of Deferred Tax Asset GoodwillSubsequentRecognitionOfDeferredTaxAsset	48000	USD
CY2016Q1	mtnb	Proceeds From Issuance Of Common Stock Net ProceedsFromIssuanceOfCommonStockNet	8500000	USD
CY2016Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	100000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	87000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	465000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	465000	USD
CY2014Q1	mtnb	Buyout Option Cost Charged To Expense BuyoutOptionCostChargedToExpense	1	USD
CY2016Q1	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	50	USD
CY2015Q1	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	325	USD
CY2016Q1	us-gaap	Depreciation Depreciation	13000	USD
CY2015Q1	us-gaap	Depreciation Depreciation	11000	USD
CY2014Q1	mtnb	Capitalized Leasing Term CapitalizedLeasingTerm	P24M
CY2016Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	39250000	shares
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	393000	USD
CY2013Q4	us-gaap	Lessor Leasing Arrangements Operating Leases Term Of Contract LessorLeasingArrangementsOperatingLeasesTermOfContract	P7Y
CY2014Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	12723	USD
CY2016Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2287	USD
CY2016Q1	us-gaap	Security Deposit SecurityDeposit	300000	USD
CY2016Q1	mtnb	Revenue Recognition Milestone Fee On Achieving Sales Threshold RevenueRecognitionMilestoneFeeOnAchievingSalesThreshold	100000	USD
CY2016Q1	dei	Document Type DocumentType	10-Q
CY2016Q1	dei	Amendment Flag AmendmentFlag	false
CY2016Q1	dei	Document Period End Date DocumentPeriodEndDate	2016-03-31
CY2016Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q1	dei	Entity Registrant Name EntityRegistrantName	Matinas BioPharma Holdings, Inc.
CY2016Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001582554
CY2016Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2016Q1	dei	Trading Symbol TradingSymbol	MTNB
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57593414	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	5719	USD
CY2016Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	29646501	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	6072403	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	4220487	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8406078	USD
CY2016Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	1205141	USD
CY2016Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	100378	USD
CY2016Q1	us-gaap	Liabilities Liabilities	2525161	USD
CY2015Q4	us-gaap	Liabilities Liabilities	2333675	USD
CY2016Q1	us-gaap	Goodwill Goodwill	1336488	USD
CY2015Q4	us-gaap	Goodwill Goodwill	1336488	USD
CY2016Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	3017377	USD
CY2015Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	3017377	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	5760	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6745648	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	100326	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	29253848	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23187164	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-25431774	USD
CY2016Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	10218	USD
CY2015Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	9225	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	1205141	USD
CY2016Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	0	USD
CY2015Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	115370	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1128534	USD
CY2016Q1	us-gaap	Other Long Term Investments OtherLongTermInvestments	115371	USD
CY2015Q4	us-gaap	Assets Assets	8406078	USD
CY2016Q1	us-gaap	Assets Assets	6745648	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1320020	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	497842	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	620564	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	610206	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	689238	USD
CY2015Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	11261	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	47530694	shares
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33938000	shares
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1177841	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1315777	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	2626254	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	2237488	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-2570111	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-2244610	USD
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35561911	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	57287955	shares
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2568618	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2237488	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1493	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7122	USD
CY2016Q1	us-gaap	Revenues Revenues	0	USD
CY2015Q1	us-gaap	Revenues Revenues	57636	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12891	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10856	USD
CY2016Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	993	USD
CY2015Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	392694	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	332683	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	0	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-15535	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-93780	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-26583	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	53	USD
CY2015Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	78	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	122722	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-104948	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	79032	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-33347	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1542551	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2322827	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4845	USD
CY2016Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2015Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-70754	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	65909	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4282734	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4282734	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1553812	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2025816	USD
CY2016Q1	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	0	USD
CY2015Q1	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	-2119689	USD
CY2014Q2	mtnb	Increase Decrease In Lease Rental Expense IncreaseDecreaseInLeaseRentalExpense	14200	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	162948	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	165896	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	168220	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	84544	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	880350	USD
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57593414	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57593414	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57180148	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57180148	shares
CY2016Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="COLOR: black; FONT-SIZE: 10pt">NOTE A Nature of Business</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="COLOR: black; FONT-SIZE: 10pt"> </font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="COLOR: black; FONT-SIZE: 10pt">[1]</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> Corporate History</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> Matinas BioPharma Holdings Inc. (“Holdings”) is a Delaware corporation formed in 2013. Holdings is the parent company of Matinas BioPharma, Inc. (“BioPharma”), and Aquarius Biotechnologies, Inc., its operating subsidiaries (“Aquarius”, and together with “Holdings” and “BioPharma”, “the Company” or “we” or “our” or “us”). The Company is a development stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">  </font></div> <font style="COLOR: black; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">On January 29, 2015, we completed the acquisition of Aquarius (“Aquarius Merger”), a New Jersey-based, early-stage pharmaceutical company focused on the development of differentiated and orally delivered therapeutics based on a proprietary, lipid-based, drug delivery platform called “cochleate delivery technology.” Following the Aquarius Merger, we are a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, using our innovative lipid-crystal nano-encapsulation drug delivery platform. See Note D for additional information on this transaction.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">On March 31, 2015 and April 10, 2015, we completed a private placement (“2015 Private Placement”), under which the Company sold an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20,000,000</font> shares of common stock and warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20,000,000</font> shares of common stock (see Note E for additional details) resulting in net proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8.5</font> million after offering expenses.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">  </font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="COLOR: black; FONT-SIZE: 10pt">[2]</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> Proprietary Products and Technology Portfolios</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Our proprietary cochleate lipid-crystal nano-particle delivery technology platform, licensed from Rutgers University on an exclusive worldwide basis, is designed specifically for the targeted and safe delivery of orally bioavailable pharmaceuticals directly to the site of infection or inflammation. This license comprises a range of issued patents and patent applications, as well as the use of proprietary know-how with respect to the manufacturing and testing of products using this technology.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">Our lead product candidate using the cochleate delivery technology is MAT2203, an oral formulation of the broad spectrum intravenous(IV)-delivered anti-fungal agent amphotericin B. MAT2203 is under development for serious fungal infections and a single-escalating-dose Phase 1 study with MAT2203 has been completed. The Company is developing MAT2203 in collaboration with the National Institute of Allergy and Infectious Diseases, or NIAID, of the National Institutes of Health, or NIH. The U.S. Food and Drug Administration (FDA) has designated MAT2203 as a Qualified Infectious Disease Product (QIDP) with Fast Track status for the treatment of aspergillus. We are developing a pipeline of targeted delivery formulations by applying our cochleate oral delivery technology to a potentially broad array of proven medications, including MAT2501. MAT2501 is an oral cochleate formulation of the broad spectrum intravenous (IV)-delivered aminoglycoside antibiotic called amikacin, which is most often used for treating severe, hospital-acquired infections, including Gram-negative bacterial infections. The Company has an open Investigational New Drug (IND) application for MAT2501. MAT2501  has been granted a QIDP designation and Orphan Drug designation by the U.S. FDA.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">In addition, the Company is exploring development and partnership options for MAT9001, a prescription-only omega-3 fatty acid-based composition under development for hypertriglyceridemia.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="COLOR: black; FONT-SIZE: 10pt">[2]</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><strong><font style="COLOR: black; FONT-SIZE: 10pt">Use of Estimates</font></strong></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in; size: 8.5in 11.0in" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in; size: 8.5in 11.0in" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in; size: 8.5in 11.0in" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in; size: 8.5in 11.0in" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> Certain accounting principles require subjective and complex judgments to be used in the preparation of financial statements. Accordingly, a different financial presentation could result depending on the judgments, estimates, or assumptions that are used. Such estimates and assumptions include, but are not specifically limited to, those required in the assessment of the impairment of intangible assets, all acquired assets and liabilities, the valuation of Level 3 financial instruments and determination of stock-based compensation.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="COLOR: black; FONT-SIZE: 10pt">[4]</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><strong><font style="COLOR: black; FONT-SIZE: 10pt">Concentration of Credit Risk</font></strong></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in; size: 8.5in 11.0in" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in; size: 8.5in 11.0in" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. Cash balances are maintained principally at one major U.S. financial institution and are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. At all times throughout the three months ended March 31, 2016, the Company’s cash balances exceeded the FDIC insurance limit. The Company has not experienced any losses in such accounts.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q1	us-gaap	Description Of Lessee Leasing Arrangements Capital Leases DescriptionOfLesseeLeasingArrangementsCapitalLeases	The payments under the lease were accounted for as interest and payments under capital lease using 2-year amortization.
CY2013Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11828912	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.04	pure
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	granted at prices not less than 100% of the fair value
CY2016Q1	mtnb	Security Deposits Reduced By Straight Line Basis Description SecurityDepositsReducedByStraightLineBasisDescription	This deposit was reduced by $100,000 in 2015 and can be reduced by $100,000 on an annual basis going forward, down to $50,000, as long as the Company makes timely rental payments.
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.9469	pure
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0122	pure
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.01375	pure
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0165	pure
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0193	pure
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0	pure
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0	pure
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3226997	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2590713	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1673185	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4616529	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-9100000	USD
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q2	mtnb	Sharebased Compensation Arrangement By Sharebased Payment Award Increase Of Shares Offering Date SharebasedCompensationArrangementBySharebasedPaymentAwardIncreaseOfSharesOfferingDate	January 1, 2015
CY2016Q1	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	138730	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	160012	USD
CY2016Q1	mtnb	Issuance Of Warrants Description IssuanceOfWarrantsDescription	The Company may call the Warrants, other than the Placement Agent Warrants, at any time the common stock trades above $5.00 (for 13 million warrants issued in 2013) or above $ 3.00 (for 20 million warrants issued in 2015) for twenty (20) consecutive days following the effectiveness of the registration statement covering the resale of the shares of common stock underlying
CY2016Q1	mtnb	Effectiveness Of Registration Statement Description EffectivenessOfRegistrationStatementDescription	The Registration Statement was filed on June 9, 2015 and declared effective on July 23, 2015. The Company is required to keep the registration statement continuously effective under the Securities Act of 1933, as amended (the “Securities Act”), for a period of one year from the date it is declared effective by the SEC or for such shorter period ending on the earlier of the date when all the registrable securities covered by the registration statement have been sold or such time as all of the securities covered by the registration statement can be sold under Rule 144 without any volume limitations (the “Effectiveness Period”). If the Company does not maintain the effectiveness of the registration statement during the Effectiveness Period, subject to certain limitations and the right of the Company to suspend the use of the prospectus for certain periods, the Company shall pay to each holder of registrable securities purchased in 2015 Private Placement an amount in cash equal to half of one percent (0.5%) of such holder’s investment amount, subject to a maximum penalty equal to six percent (6%) of such holder’s investment amount, on every thirty (30) day anniversary of such failure to maintain the registration statement until such failure was cured; provided however that such liquidated damages shall be paid only with respect to registrable securities that cannot then be immediately resold in reliance on Rule 144.

Files In Submission

Name	View Source	Status
0001144204-16-101865-index-headers.html	Edgar Link	pending
0001144204-16-101865-index.html	Edgar Link	pending
0001144204-16-101865.txt	Edgar Link	pending
0001144204-16-101865-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mtnb-20160331.xml	Edgar Link	completed
mtnb-20160331.xsd	Edgar Link	pending
mtnb-20160331_cal.xml	Edgar Link	unprocessable
mtnb-20160331_def.xml	Edgar Link	unprocessable
mtnb-20160331_lab.xml	Edgar Link	unprocessable
mtnb-20160331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v438102_10q.htm	Edgar Link	pending
v438102_ex31-1.htm	Edgar Link	pending
v438102_ex31-2.htm	Edgar Link	pending
v438102_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MTNB
Matinas BioPharma Holdings, Inc. Stock $mtnb

2016 Q2 Form 10-Q Financial Statement

#000114420416101865 Filed on May 13, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MTNB Matinas BioPharma Holdings, Inc. Stock $mtnb

2016 Q2 Form 10-Q Financial Statement

#000114420416101865 Filed on May 13, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MTNB
Matinas BioPharma Holdings, Inc. Stock $mtnb